Carboplatin Alone vs Carboplatin plus Epidoxorubicin as Second-Line Therapy for Cisplatin- or Carboplatin-Sensitive Ovarian Cancer

Author: Bolis G.   Scarfone G.   Giardina G.   Villa A.   Mangili G.   Melpignano M.   Presti M.   Tateo S.   Franchi M.   Parazzini F.   on behalf of the Associazione per la Ricerca in Ginecologia Oncologica ARGO 96 Study Group  

Publisher: Elsevier

ISSN: 0090-8258

Source: Gynecologic Oncology, Vol.81, Iss.1, 2001-04, pp. : 3-9

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content